The Q Fever market is anticipated to reach USD 4213.38 Million by 2030 at 4.60% CAGR during the forecast period 2022-2030. Bacterial infections are common all over the world. Such infections could develop is various conditions and environment. Q fever is usually associated with birds and mammals and could transfer to human. It is an occupation disease, usually diagnosed in people working in slaughterhouse, veterinary, animal farms, etc.
The effect of Q fever infection is mostly chronic however few cases may become acute. Some of the complications include encephalitis, hepatitis, splenomegaly, endocarditis and pneumonia. In acute q fever, hospitalization is highly likely.
Competitive Landscape
Merck KGaA (Germany), Pfizer Inc. (US), Sanofi S.A. (France), Bayer AG (Germany), Yashica Pharmaceuticals (India), Teva Pharmaceutical (Israel), Melinta Therapeutics, Inc. (US), Basilea Pharmaceutica Ltd (Switzerland), AtoxBio (US), and Johnson & Johnson Services, Inc. (US) are among the top-notch market players discussed in MRFR’s report.
Segmental Overview
MRFR’s report include a detailed segmental analysis of the global q fever market based on type, diagnosis, end user and treatment.
On the basis of type, the market has been segmented into chronic and acute. The chronic segment accounts for a larger market share and is likely to retain its market position over 2023. The segment is expected to surpass a market valuation of USD 700 thousand towards the end of forecast period. Chronic Q fever is known to effect vital organs such as lungs, brain, heart, and liver and can prove fatal. Chronic Q is also linked with onset of diabetes.
On the basis of diagnosis, the market has been segmented into serology test & others. The serology test segment is expected to remain highly attractive over the next several years. The segment is expected to exhibit a CAGR of 8.32% during the assessment period. In serology test, there are different diagnosis procedures such as enzyme-linked immunosorbent assay (ELISA) tests, polymerase chain reaction (PCR) tests, antibody blood tests, complement fixation, immunoperoxidase staining, among others.
On the basis of treatment, the market has been segmented into surgery and antibiotics. The former will continue to outperform the later during the forecast period. A large number of q fever cases require surgery.
Global Q Fever Market: Regional Segmentation
Asia Pacific, Americas (North America and South America), Europe are among the key regions covered in MRFR’s analysis. Asia Pacific is the largest market for q fever. In 2017, APAC accounted for 44.5% share of the global Q fever market in terms of revenue and is projected to capture 8.57% CAGR during the assessment period. High prevalence of bacterial infection, and high risk of epidemic developing countries in the region makes q fever a prudent disease in APAC. China and India have emerged as the two most significant markets for q fever in APAC. In addition, governments in these countries are increasing their focus on improving healthcare services as well as undertaking initiatives to spread awareness.
After Asia Pacific, the Q fever market is most attractive in Europe and North America. This is mainly due to factors such as high healthcare expenditure, high level of awareness and strong healthcare penetration. Prevalence of animal-transmitted diseases in these regions is moderate owing to existence of robust precautionary measures.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
